Carcinoma, Pancreatic Ductal

The grounding supports an association with oncogenic mutations, especially KRAS, which is mutated in up to 90% of pancreatic ductal adenocarcinomas. It also notes contributions from the tumor secretome, non-coding RNAs, and the tumor microbiome in disease progression, but does not support a single definitive cause.

The disease is characterized by aggressive tumor biology, immunosuppression, and a prominent desmoplastic stromal microenvironment. This microenvironment creates dense, hypoxic, physical, and immunologic barriers that promote tumorigenesis, support local growth and metastasis, and contribute to therapy resistance.

Late detection is a major challenge in this disease, but the grounding does not support specific patient-level risk factors. It does support biologic features associated with worse behavior, including KRAS-driven oncogenesis, immunosuppressive microenvironmental states, and stromal desmoplasia.

The mainstay of treatment for metastatic pancreatic ductal adenocarcinoma is cytotoxic chemotherapy. The grounding specifically identifies fluorouracil-, oxaliplatin-, gemcitabine-, and paclitaxel-based therapy as relevant, and notes NALIRIFOX as an emerging standard in the metastatic setting. It also supports combined-modality approaches, including radio(chemo)therapy, and targeted therapy in selected molecular subsets such as BRCA-mutated disease or tumors with rare fusions or mismatch repair deficiency.